Content : Lenvatinib

Dosage Form : 4mg and 10 mg hard capsules

Indication :

LENVIMA is indicated for the treatment of adults patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

LENVIMA is indicated as monotherapy for the treatment of adults patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.